The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia
Aim: Monitoring of cardiotoxicity of conventional and high-dose chemotherapy (HD-CT) with multiple biomarkers of cardiac injury — glycogen phosphorylase BB (GPBB), heart-type fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Methods: A t...
Збережено в:
| Дата: | 2010 |
|---|---|
| Автори: | , , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2010
|
| Назва видання: | Experimental Oncology |
| Теми: | |
| Онлайн доступ: | http://dspace.nbuv.gov.ua/handle/123456789/138602 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia / J.M. Horacek, M. Vasatova, M. Tichy, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2010. — Т. 32, № 2. — С. 97-99. — Бібліогр.: 26 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
irk-123456789-138602 |
|---|---|
| record_format |
dspace |
| spelling |
irk-123456789-1386022018-06-20T03:07:13Z The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia Horacek, J.M. Vasatova, M. Tichy, M. Pudil, R. Jebavy, L. Maly, J. Original contributions Aim: Monitoring of cardiotoxicity of conventional and high-dose chemotherapy (HD-CT) with multiple biomarkers of cardiac injury — glycogen phosphorylase BB (GPBB), heart-type fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Methods: A total of 47 adult acute leukemia patients were studied — 24 patients treated with conventional CT containing anthracyclines (ANT) and 23 patients treated with HD-CT (myeloablative preparative regimen) followed by hematopoietic cell transplantation (HCT). Cardiac biomarkers were assessed prior to treatment (before CT/HD-CT), after first CT with ANT, after last CT with ANT in the first group, after HD-CT and after HCT in the second group. Values above the reference range were considered elevated. Results: Before CT/HD-CT, all biomarkers of cardiac injury were below the cut-offs in all patients. GPBB increased above the cut-off (7.30 μg/L) in 4 (16.7%) patients after first CT and in 5 (20.8%) patients after last CT with ANT. GPBB increased above the cut-off in 5 (21.7%) patients after HD-CT and remained elevated in 5 (21.7%) patients after HCT. CTnI became elevated (above 0.40 μg/L) in 2 (8.3%) patients after first and last CT with ANT. Both patients with cTnI positivity had elevated GPBB. Other tested biomarkers remained below the cut-offs during the study. Conclusion: Our results suggest that GPBB could become a sensitive biomarker for detection of acute cardiotoxicity associated with conventional CT containing ANT and HD-CT followed by HCT. The predictive value for development of cardiomyopathy in the future is not known and should be evaluated during a prospective follow-up. Based on our data, a larger prospective and multicenter study would be most desirable to define the potential role of new circulating biomarkers in the assessment of cardiotoxicity in oncology. 2010 Article The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia / J.M. Horacek, M. Vasatova, M. Tichy, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2010. — Т. 32, № 2. — С. 97-99. — Бібліогр.: 26 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/138602 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| language |
English |
| topic |
Original contributions Original contributions |
| spellingShingle |
Original contributions Original contributions Horacek, J.M. Vasatova, M. Tichy, M. Pudil, R. Jebavy, L. Maly, J. The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia Experimental Oncology |
| description |
Aim: Monitoring of cardiotoxicity of conventional and high-dose chemotherapy (HD-CT) with multiple biomarkers of cardiac injury — glycogen phosphorylase BB (GPBB), heart-type fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Methods: A total of 47 adult acute leukemia patients were studied — 24 patients treated with conventional CT containing anthracyclines (ANT) and 23 patients treated with HD-CT (myeloablative preparative regimen) followed by hematopoietic cell transplantation (HCT). Cardiac biomarkers were assessed prior to treatment (before CT/HD-CT), after first CT with ANT, after last CT with ANT in the first group, after HD-CT and after HCT in the second group. Values above the reference range were considered elevated. Results: Before CT/HD-CT, all biomarkers of cardiac injury were below the cut-offs in all patients. GPBB increased above the cut-off (7.30 μg/L) in 4 (16.7%) patients after first CT and in 5 (20.8%) patients after last CT with ANT. GPBB increased above the cut-off in 5 (21.7%) patients after HD-CT and remained elevated in 5 (21.7%) patients after HCT. CTnI became elevated (above 0.40 μg/L) in 2 (8.3%) patients after first and last CT with ANT. Both patients with cTnI positivity had elevated GPBB. Other tested biomarkers remained below the cut-offs during the study. Conclusion: Our results suggest that GPBB could become a sensitive biomarker for detection of acute cardiotoxicity associated with conventional CT containing ANT and HD-CT followed by HCT. The predictive value for development of cardiomyopathy in the future is not known and should be evaluated during a prospective follow-up. Based on our data, a larger prospective and multicenter study would be most desirable to define the potential role of new circulating biomarkers in the assessment of cardiotoxicity in oncology. |
| format |
Article |
| author |
Horacek, J.M. Vasatova, M. Tichy, M. Pudil, R. Jebavy, L. Maly, J. |
| author_facet |
Horacek, J.M. Vasatova, M. Tichy, M. Pudil, R. Jebavy, L. Maly, J. |
| author_sort |
Horacek, J.M. |
| title |
The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia |
| title_short |
The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia |
| title_full |
The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia |
| title_fullStr |
The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia |
| title_full_unstemmed |
The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia |
| title_sort |
use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| publishDate |
2010 |
| topic_facet |
Original contributions |
| url |
http://dspace.nbuv.gov.ua/handle/123456789/138602 |
| citation_txt |
The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia / J.M. Horacek, M. Vasatova, M. Tichy, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2010. — Т. 32, № 2. — С. 97-99. — Бібліогр.: 26 назв. — англ. |
| series |
Experimental Oncology |
| work_keys_str_mv |
AT horacekjm theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT vasatovam theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT tichym theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT pudilr theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT jebavyl theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT malyj theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT horacekjm useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT vasatovam useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT tichym useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT pudilr useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT jebavyl useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia AT malyj useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia |
| first_indexed |
2023-10-18T21:18:27Z |
| last_indexed |
2023-10-18T21:18:27Z |
| _version_ |
1796152468619395072 |